NantCell gets license to Amgen's Phase II oncology candidate

10 Apr 2017

NantWorks LLC’s NantCell LLC received exclusive global rights (except in Japan) to Amgen Inc.’s AMG479 (ganitumab) cancer compound.

Pharmaceuticals
Biotechnology
- Large Molecule
  - Antibodies
- Drug Discovery Technologies
  - Genomics-Proteomics

Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing

Already a Biomedtracker subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email [email protected]

Related Companies

NantCell gets license to Amgen's Phase II oncology candidate

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice